Nyxoah (NYXH) Projected to Post Earnings on Tuesday

Nyxoah (NASDAQ:NYXH) is anticipated to post its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Nyxoah to post earnings of ($0.54) per share and revenue of $7.0490 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

Nyxoah (NASDAQ:NYXH) last posted its earnings results on Saturday, February 14th. The company reported ($0.69) EPS for the quarter. The firm had revenue of $6.62 million during the quarter. Nyxoah had a negative net margin of 884.69% and a negative return on equity of 139.18%. On average, analysts expect Nyxoah to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Nyxoah Trading Up 1.7%

Nyxoah stock traded up $0.05 during trading hours on Tuesday, hitting $2.93. The stock had a trading volume of 29,815 shares, compared to its average volume of 49,186. The company has a quick ratio of 1.16, a current ratio of 1.25 and a debt-to-equity ratio of 0.37. The stock has a market cap of $113.57 million, a price-to-earnings ratio of -1.09 and a beta of 1.56. Nyxoah has a one year low of $2.76 and a one year high of $8.64. The business’s 50 day simple moving average is $3.38 and its 200-day simple moving average is $4.38.

Institutional Investors Weigh In On Nyxoah

A number of hedge funds have recently added to or reduced their stakes in NYXH. Raymond James Financial Inc. increased its holdings in Nyxoah by 35.6% in the third quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock worth $59,000 after purchasing an additional 3,353 shares in the last quarter. Bank of America Corp DE increased its stake in Nyxoah by 72.4% in the second quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock valued at $59,000 after purchasing an additional 3,303 shares in the last quarter. Citadel Advisors LLC bought a new stake in Nyxoah in the third quarter valued at $98,000. Deutsche Bank AG increased its stake in Nyxoah by 40.0% in the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Shay Capital LLC bought a new stake in Nyxoah in the second quarter valued at $374,000.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on NYXH. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $11.00 price target on shares of Nyxoah in a research note on Monday, March 23rd. Weiss Ratings downgraded Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 22nd. Finally, Stifel Nicolaus lowered their price objective on Nyxoah from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, April 10th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.33.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.